Therapeutic Targeting of Overexpressed MiRNAs in Cancer Progression

MicroRNAs (miRNAs) are non-coding RNAs involved in the modulation of various biological processes, and their dysregulation is greatly associated with cancer progression as miRNAs can act as either tumour suppressors or oncogenes, depending on their intended target, mechanism of actions, and expressi...

Full description

Saved in:
Bibliographic Details
Published inCurrent drug targets Vol. 23; no. 13; p. 1212
Main Authors Lee, Sau Har, Brianna, Brianna
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2022
Subjects
Carrier Proteins - metabolism
Cell Proliferation
Gene Expression Regulation, Neoplastic
Genes, Tumor Suppressor
Humans
MicroRNAs - genetics
Neoplasms - genetics
Nerve Tissue Proteins - genetics
Nerve Tissue Proteins - metabolism
Oncogenes
SOXF Transcription Factors - genetics
SOXF Transcription Factors - metabolism
tumor suppressor genes
antisense miRNAs
cancer therapeutic
miRNA dysregulation
anticancer
Overexpressed miRNAs
Online AccessGet more information

Cover

More Information
Summary:MicroRNAs (miRNAs) are non-coding RNAs involved in the modulation of various biological processes, and their dysregulation is greatly associated with cancer progression as miRNAs can act as either tumour suppressors or oncogenes, depending on their intended target, mechanism of actions, and expression levels. This review paper aims to shed light on the role of overexpressed miRNAs in cancer progression. Cancer cells are known to upregulate specific miRNAs to inhibit the expression of genes regulating the cell cycle, such as PTEN, FOXO1, SOX7, caspases, KLF4, TRIM8, and ZBTB4. Inhibition of these genes promotes cancer development and survival by inducing cell growth, migration, and invasion while evading apoptosis, which leads to poor cancer survival rates. Therefore, the potential of antisense miRNAs in treating cancer is also explored in this review. Antisense miRNAs are chemically modified oligonucleotides that can reverse the action of overexpressed miRNAs. Currently, the therapeutic potential of antisense miRNAs is being validated in both in vitro and in vivo models. Studies have shown that antisense miRNAs could slow down the progression of cancer while enhancing the action of conventional anticancer drugs. These findings provide hope for future oncologic care as this novel intervention is in the process of clinical translation.
ISSN:1873-5592
DOI:10.2174/1389450123666220613163906